AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05650944 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hemogram
Description: Sysmex XN-1000 hematological analyzer
Study NCT01354392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1152
Description: Up to 6 cycles. Each cycle consists of 800 mg. IV infusion over 96 hrs.
Study NCT00132379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABR-217620
Description: 10.3, 16.5 or 22 mcg/kg, IV, daily 5 minute bolus injection for 4 consecutive day per cycle; up to 6 cycles
Study NCT00132379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 75mg/m\^2, IV, single 60 minute infusion, beginning on Day 5 then every third week
Study NCT00960674 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tactile massage
Description: Gentle massage given for one hour by specially educated massage therapists, usually registered nurses.
Study NCT00960674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation
Description: Relaxation by a CD with relaxation exercises, at least one hour per week for ten weeks
Study NCT03355105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Objective adjustment of the MI/E exsuflation pressure and evaluation of cough effort
Description: The exsufflation pressures will be progressively increased starting from -20 cmH2O with 10 cmH2O increments up. 3 coughing operations will be realised for each level, until obtention of 10% of AUC decrease or a PCF collapse of at least 10% over the last 2 levels and without exceeding -70 cmH2O. The selected landing will be the one allowing the largest PCF without presence of collapse. An intermediate bearing between 2 bearings may be tested in order to approach an optimum adjustment threshold less than 5 cmH2O.
Study NCT03632629 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: interactive cognitive training
Description: Using interactive brain club system training to children with attention deficit hyperactivity disorder with developmental delay
Study NCT03495674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete cycling classes
Study NCT03495674 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive information about exercise guidelines
Study NCT03495674 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring Device
Description: Wear Fitbit
Study NCT03495674 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring Device
Description: Wear Fitbit
Study NCT03355105 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Subjective adjustment of the MI/E exsuflation pressure and evaluation of cough effort
Description: The exsufflation pressures will be gradually increased from -20 cmH2O, with 10 cmH2O increments up to a maximum of -70 cmH2O. The selected level will be the one selected both by the patient and the clinician therapist and considered as making it possible to obtain the most effective cough according to the return of the patient.
Study NCT02826525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4076
Description: Investigational product
Study NCT02826525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control
Study NCT00882921 — intervention group
Intervention type: BIOLOGICAL
Intervention: Idursulfase
Description: Patients received idursulfase as prescribed by their physician following locally approved prescribing information. Patients will not be provided idursulfase by Shire Human Genetic Therapies, Inc. or the HOS.
Study NCT04437147 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fibers with vitamins and minerals will be administered for 30 days once a day in sachets
Study NCT04437147 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 3 Billion UFC strains of probiotics
Description: Fibers with vitamins and minerals will be administered for 30 days once a day in sachets with 3 billion CFU strains of probiotics
Study NCT04437147 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 8 Billion UFC strains of probiotics
Description: Fibers with vitamins and minerals will be administered for 30 days once a day in sachets with 8 billion CFU strains of probiotics
Study NCT01756820 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-portal Endoscopic Carpal Tunnel Release (Microaire®)
Description: SmartRelease® ECTR endoscopic carpal tunnel release system of MicroAire (http://www.microaire.com/products/ectr-endoscopic-carpal-tunnel/smart-release-ctrs/).
Study NCT01756820 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Knifelight
Description: A mini-open single portal technique using the Knifelight® device (Stryker) according to the surgical technique as described by the manufacturer (antegrade approach)
Study NCT01007968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Study NCT03184922 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adjustable versus fixed suspensory loop femoral side graft fixation
Description: A comparison of 2 different types of surgical technique for attaching the femoral side graft in ACL reconstruction: with a fixed suspensory loop or an adjustable one
Study NCT03184922 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adjustable versus fixed suspensory loop femoral side graft fixation
Description: A comparison of 2 different types of surgical technique for attaching the femoral side graft in ACL reconstruction: with a fixed suspensory loop or an adjustable one
Study NCT00819065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A from laboratory Lanzhou
Description: Patients will receive botulinum toxin type A from laboratory Lanzhou either at time of allocation (arm BTA Lanzhou/Allergan) or three months later (arm BTA Allergan/Lanzhou), so that all patients will receive both drugs in a crossover model. Application will be performed according to standard protocol and respecting parameters of the patients former sessions (if there were any), by a trained investigator, unaware of the kind of TBA in use. Standard dilution will be employed, within the usual dose and application spots (for patients already in treatment) or standard (for patients yet to start treatment). Identical dose will be used, with 2ml of saline solution 0,9% dilution for each 100units, thus, there will be no difference for the patient or investigator concerning the applicated volume.
Study NCT00819065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A from laboratory Allergan
Description: Patients will receive botulinum toxin type A from laboratory Allergan either at time of allocation (arm BTA Allergan / Lanzhou) or three months later (arm BTA Lanzhou /Allergan), so that all patients will receive both drugs in a crossover model. Application will be performed according to standard protocol and respecting parameters of the patients former sessions (if there were any), by a trained investigator, unaware of the kind of BTA in use. Standard dilution will be employed, within the usual dose and application spots (for patients already in treatment) or standard (for patients yet to start treatment). Identical dose will be used, with 2ml of saline solution 0,9% dilution for each 100units, thus, there will be no difference for the patient or investigator concerning the applicated volume.
Study NCT00049400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-247550
Description: BMS-247550 as a 3-hour infusion on Day 1 of a three-week cycle
Study NCT02568332 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh3NSmut1
Description: Genetic vaccine against Hepatitis C virus infection
Study NCT02568332 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-NSmut
Description: Genetic vaccine against Hepatitis C virus infection
Study NCT01112696 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sensor wear
Description: All subjects to wear sensors
Study NCT02477397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spiromax Budesonide/formoterol
Description: 1. In Group A, Patients will be treated with Spiromax® budesonide/formoterol 160/4.5 μg two inhalations twice daily + Spiromax® budesonide/formoterol 160/4.5 μg as needed with a maximum of 8 additional inhalations daily.
Study NCT02477397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diskus Fluticasone/salmeterol
Description: 2. In group B, Patients will be treated with Diskus® fluticasone/salmeterol 500/50 μg one inhalation twice daily + salbutamol 100 μg as needed with a maximum of 8 inhalations daily.
Study NCT03997058 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular point pressure therapy
Description: Use a hard and smooth pill to adhere to the center of the 0.7×0.7cm tape. Hold the puncture clip on the part of the ear which is selected, and give appropriate pressure (揉) to make the patient have heat, hemp, Swelling and painful feeling; patients with sputum press 3-5 times a day, each time 1-2 minutes per hole, and must be pressed once every 15-30 minutes before going to bed every night. Press the point pressure method (press the ear point with a fingertip and press it loosely, each interval is 0.5 seconds. It is better for the patient to feel the swelling and slightly heavy tingling, and the force should not be too heavy. Generally, each time the hole can be pressed 27 times. Each time one side of the ear is selected, the two ear points are used alternately, staying in the summer for 1-3 days, and staying in the winter for 3-7 days.It is not appropriate to have local inflammation of the auricle, frostbite or surface skin ulceration.
Study NCT03997058 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auricular point pressure therapy
Description: Use a hard and smooth pill to adhere to the center of the 0.7×0.7cm tape. Hold the puncture clip on the part of the ear which is selected, and give appropriate pressure (揉) to make the patient have heat, hemp, Swelling and painful feeling; patients with sputum press 3-5 times a day, each time 1-2 minutes per hole, and must be pressed once every 15-30 minutes before going to bed every night. Press the point pressure method (press the ear point with a fingertip and press it loosely, each interval is 0.5 seconds. It is better for the patient to feel the swelling and slightly heavy tingling, and the force should not be too heavy. Generally, each time the hole can be pressed 27 times. Each time one side of the ear is selected, the two ear points are used alternately, staying in the summer for 1-3 days, and staying in the winter for 3-7 days.It is not appropriate to have local inflammation of the auricle, frostbite or surface skin ulceration.
Study NCT03997058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral estazolam medication
Description: The first dose was started from 0.5mg, qn, and taken at 30min-1h before going to bed. If the dose is not effective, gradually increase the amount to 2mg, qn. If the patient has drug-induced liver damage and respiratory depression, it is necessary to stop the drug immediately. Hemorrhoids avoid drinking alcohol during medication.
Study NCT02779595 — intervention group
Intervention type: OTHER
Intervention: Perioperative pulmonary function tests
Description: Pulmonary electrical impedance tomography, spirometry, pulse oximetry and query performed preoperatively, at the the third, fifth and seventh postoperative day
Study NCT02138747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Oral
Study NCT03495674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study NCT03495674 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study NCT02138747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine ER
Description: Oral
Study NCT02332018 — intervention group
Intervention type: RADIATION
Intervention: Biplanar x-ray images
Description: biplanar x-ray images with microdose and low-dose protocol
Study NCT02703207 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positive airway pressure
Description: CPAP will be applied as standard of care for diagnosis of moderate to severe OSA
Study NCT04440891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS stimulation with X-Torp task
Description: TMS-Stimulation with X-Torp task
Study NCT04440891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS-Stimulation with MindMotion Go
Description: TMS-Stimulation with MindMotion Go
Study NCT04440891 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS-Sham with X-Torp task
Description: TMS-Sham with X-Torp task
Study NCT04440891 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS-Sham with MindMotion Go
Description: TMS-Sham with MindMotion Go
Study NCT03474016 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Mammography-Histopathological examination of breast mass specimens- polymerase chain reaction
Description: Mammography-Histopathological examination of breast mass specimens-Detection of long and short DNA fragments in serum using real-time quantitative polymerase chain reaction
Study NCT00217776 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Open Airways Educational Intervention
Study NCT00217776 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer Asthma Action Educational Intervention
Study NCT03845361 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radial artery cannulation
Description: Radial artery cannulation
Study NCT02703207 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIPPV and /or oxygen
Description: supplemental oxygen will be applied to PAP/non-invasive positive pressure therapy
Study NCT01985828 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife
Study NCT01985828 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy (ADT)
Study NCT01985828 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated radiation therapy (IMRT)
Description: Per current standard of care
Study NCT02287116 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Easy Flow system and INCA® nasal cannulae set
Study NCT03295266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3866
Description: Single IV infusion of MK-3866 150 mg administered over 30 minutes at Hour 0 on Day 1 of treatment period.
Study NCT04527848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: small amount of undiluted C3F8
Description: vitrectomy followed by peeling of the internal limiting membrane and, after that, intraocular gas injection
Study NCT04527848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: small amount of undiluted C3F8
Description: vitrectomy followed by peeling of the internal limiting membrane and, after that, intraocular gas injection
Study NCT03001232 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Movement-oriented Dementia Care
Description: The intervention is a new multidisciplinary approach that focuses on optimizing physical activity and independence in daily care and activities. MDC intended to incorporate all persons surrounding the patients. The nursing staff was intensively trained by an expert in MDC, and played a central role in continuously stimulating patients to function as independently as possible. Geriatric physicians and physiotherapists advised the nursing staff about participants' medical and physical limitations to ensure safe stimulation. Consequently, a plan was created for each resident to determine the daily routines they were capable of performing themselves. Caregivers and volunteers were informed about the benefits of an active lifestyle during several open meetings.
Study NCT03324503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoid (prednisone or prednisolone)
Description: ≥ 30 mg/day prednisone or prednisolone taken orally as per local clinical practice of sarcoidosis initial induction therapy
Study NCT02571946 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton beam therapy
Study NCT00812188 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medium Dose UVA-1
Description: UVA-1 phototherapy treatment (60 J/cm2) three times per week for 12 weeks.
Study NCT00812188 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Dose UVA-1
Description: High dose (120 J/cm2)UVA-1 phototherapy three times per week for 12 weeks.
Study NCT00194480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon
Description: Weekly injections of pegIntereferon
Study NCT00058227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV
Study NCT00058227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT00058227 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT00058227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT03395470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXL770
Description: MAD
Study NCT03395470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: MAD
Study NCT01394484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention I
Description: Four servings of dairy foods (milk and yogurt) per day for 42 days.
Study NCT03395470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: DDI
Study NCT01550081 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rate of perceived exertion
Description: Exercise intensity controlled by Borg scale
Study NCT01550081 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heart rate monitor
Description: Exercise intensity controlled by heart rate monitors
Study NCT01394484 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention II
Description: 1200 mg of supplemental calcium and 400 IU of vitamin D3 for 42 days
Study NCT02005315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vantictumab
Description: Administered intravenous (IV) infusion.
Study NCT02005315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel will be administered by intravenous (IV) infusion.
Study NCT02005315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered by intravenous (IV) infusion.
Study NCT03734991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrexafungerp
Description: Ibrexafungerp 300 mg BID for 1 day
Study NCT03734991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT03324399 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic
Description: a proprietary probiotic formulation
Study NCT00346801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 100 mg by mouth (PO) twice daily for 5 days before beginning radiation therapy; continued 7 days per week throughout radiation treatment (about 7 weeks).
Study NCT00346801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25 mg/m\^2 IV over 60 minutes on Day 1, Weeks 2-8
Study NCT00346801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPT-11
Description: 30 mg/m\^2 IV over 90 minutes on Day 1, Weeks 2-8, followed by cisplatin which will be infused for 60 minutes.
Study NCT00346801 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent Thoracic Radiation Therapy
Description: 63 Gy at 1.8 Gy/Fx in 35 Fractions over 7 weeks starting 2nd week of celebrex.
Study NCT04596033 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-011
Description: Personalized neoantigen adoptive cell therapy (ACT)
Study NCT04596033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Cytokine
Study NCT03334071 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: High intensity interspersed with short periods of exercise at a moderate intensity (aerobic interval training). We will also include resistance training in each session.~The supervised in-hospital exercise training sessions will last \<1 hour, exercise training intensities will be individually tailored to each CPET. Exercise training will involve repeated exercise bouts of 3 minutes at a moderate exercise intensity (80%AT) followed by 2 minutes of exercise at a high intensity (50%Δ) for a predetermined amount of time.~The home-based training programme will involve stair climbing (where possible) and brisk walking to achieve heart rates commensurate with those achieved during the in-hospital exercise training sessions.
Study NCT00377312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parathyroid Hormone (1-34)
Description: PTH(1-34) IV given over a one week period
Study NCT00626158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000 mg/m2 IV day 1 of every cycle for 100 minutes (each cycle 14 days)
Study NCT04596033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepletion drug
Study NCT04596033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepletion drug